Peter Gerrit Johannes ter Horst
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Peter Gerrit Johannes ter Horst has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
- Mireille A. Edens
Epidemiology Unit, Department Innovation and Science, Isala Hospital, Zwolle, The Netherlands
4 shared publications - André Wieringa
Department of clinical pharmacy, Isala hospital, Zwolle, the Netherlands
3 shared publications Bob Wilffert
Department of PharmacoTherapy, Epidemiology & Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands
3 shared publications- Elise Joelle Smolders
Department of clinical pharmacy, Isala hospital, Zwolle, the Netherlands
3 shared publications Jan Pieter Smit
Isala Department of Psychiatry, Zwolle, The Netherlands
3 shared publicationsBas Nij Bijvank
2 shared publications
Latest Publications
- 22 December 2025
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 82 (1) , 10
Lacosamide concentration-dose (C/D) ratios during pregnancy: a case series
- 22 December 2025
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 82 (1) , 10
Lacosamide concentration-dose (C/D) ratios during pregnancy: a case series
- Open Access
- 18 July 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (7) , e0326795
Medication, age and abstinence days associated with low semen quality: A cross-sectional study in more than 7000 men visiting the centre for reproductive medicine
Medication can affect semen quality by decreasing ejaculate volume, sperm concentration, or decreased sperm motility and sperm function in general. We performed a retrospective explorative cross-sectional study on any medication use and semen quality in our fertility clinic in men older than 18 years with a recorded semen analysis. Men were categorized based on medication use, i.e., any type, and no medication use. Exclusion criteria were incomplete semen analysis, azoospermia, a semen analysis after vasectomy, and days of abstinence less than 2 or more than 7 days before semen collection. The primary outcome was the composite endpoint of low semen quality (LSQ) according to the WHO. In total 722 men with medication and 6716 men without medication were included in the study. At the ATC-7 level (individual drug ATC-code), univariate (borderline) statistically significant associations using a cut-off of p < 0.100 were found for metformin (A10BA02), metoprolol (C07AB02) and lisinopril (C09AA03), which remained significant after adjustment for age and abstinence days. Our study is limited by the fact that information regarding exposure to information, as information was self-reported by patients. Also, the outcome, semen quality, was hindered by patients own collection. Even if a drug had logically been used for some time before semen sampling (e.g., medication for chronic disease), there was no way to determine whether that medication had been started before or after the occurrence of LSQ. Finally, medication and disease cannot be separated, hence it could not be determined whether the medication or the disease itself was associated with LSQ. Therefore, this study should be interpreted as a hypothesis-generating study.
- 18 July 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (7) , e0326795
Open AccessMedication, age and abstinence days associated with low semen quality: A cross-sectional study in more than 7000 men visiting the centre for reproductive medicine
Medication can affect semen quality by decreasing ejaculate volume, sperm concentration, or decreased sperm motility and sperm function in general. We performed a retrospective explorative cross-sectional study on any medication use and semen quality in our fertility clinic in men older than 18 years with a recorded semen analysis. Men were categorized based on medication use, i.e., any type, and no medication use. Exclusion criteria were incomplete semen analysis, azoospermia, a semen analysis after vasectomy, and days of abstinence less than 2 or more than 7 days before semen collection. The primary outcome was the composite endpoint of low semen quality (LSQ) according to the WHO. In total 722 men with medication and 6716 men without medication were included in the study. At the ATC-7 level (individual drug ATC-code), univariate (borderline) statistically significant associations using a cut-off of p < 0.100 were found for metformin (A10BA02), metoprolol (C07AB02) and lisinopril (C09AA03), which remained significant after adjustment for age and abstinence days. Our study is limited by the fact that information regarding exposure to information, as information was self-reported by patients. Also, the outcome, semen quality, was hindered by patients own collection. Even if a drug had logically been used for some time before semen sampling (e.g., medication for chronic disease), there was no way to determine whether that medication had been started before or after the occurrence of LSQ. Finally, medication and disease cannot be separated, hence it could not be determined whether the medication or the disease itself was associated with LSQ. Therefore, this study should be interpreted as a hypothesis-generating study.
- 4 July 2024
- Published by Elsevier in General Hospital Psychiatry
- Vol. 90, 76-83
A pilot study on in-utero exposure to psychotropic drugs: A comparison of pharmacological classes on neonatal and maternal outcomes
- 4 July 2024
- Published by Elsevier in General Hospital Psychiatry
- Vol. 90, 76-83
A pilot study on in-utero exposure to psychotropic drugs: A comparison of pharmacological classes on neonatal and maternal outcomes
- Open Access
- 16 May 2024
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 133, 111030
The impact of pregnancy on the pharmacokinetics of antiseizure medications: A systematic review and meta-analysis of data from 674 pregnancies
- 16 May 2024
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 133, 111030
Open AccessThe impact of pregnancy on the pharmacokinetics of antiseizure medications: A systematic review and meta-analysis of data from 674 pregnancies
- 1 February 2024
- Published by SAGE Publications in Breastfeeding Medicine
- Vol. 19 (2) , 134-136
Anidulafungin Levels in Breast Milk After Cessation of Treatment: A Case Report
Background: Anidulafungin has poor oral bioavailability, with hardly any available information on how it affects breast milk, oral absorption, or gastrointestinal side effects in the infant. Case Presentation: A 40-year-old woman who recently gave birth to a healthy infant was treated for a period of 14 days for a Candida glabrata with 100 mg anidulafungin once a day. The department of clinical pharmacy was consulted to provide advice on how long the patient had to wait after ceasing anidulafungin before it was safe to start breastfeeding, with regard to preventing possible side effects of the drug to the infant, such as diarrhea or cholestasis and increase in liver enzyme values. The advice of the hospital pharmacist was pragmatic: to start breastfeeding within 2 days after the medication was discontinued based on half-time. Results: Owing to this lack of information, we measured anidulafungin concentrations in breast milk and found low levels. Conclusion: We concluded that anidulafungin is detectable in breast milk until 32 hours after anidulafungin treatment was stopped, and that no side effects were observed by the infant.
- 1 February 2024
- Published by SAGE Publications in Breastfeeding Medicine
- Vol. 19 (2) , 134-136
Anidulafungin Levels in Breast Milk After Cessation of Treatment: A Case Report
Background: Anidulafungin has poor oral bioavailability, with hardly any available information on how it affects breast milk, oral absorption, or gastrointestinal side effects in the infant. Case Presentation: A 40-year-old woman who recently gave birth to a healthy infant was treated for a period of 14 days for a Candida glabrata with 100 mg anidulafungin once a day. The department of clinical pharmacy was consulted to provide advice on how long the patient had to wait after ceasing anidulafungin before it was safe to start breastfeeding, with regard to preventing possible side effects of the drug to the infant, such as diarrhea or cholestasis and increase in liver enzyme values. The advice of the hospital pharmacist was pragmatic: to start breastfeeding within 2 days after the medication was discontinued based on half-time. Results: Owing to this lack of information, we measured anidulafungin concentrations in breast milk and found low levels. Conclusion: We concluded that anidulafungin is detectable in breast milk until 32 hours after anidulafungin treatment was stopped, and that no side effects were observed by the infant.
- 29 January 2024
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 310 (1) , 161-170
Risks associated with antidepressants in patients with hypertension during pregnancy: a retrospective cohort study
Purpose In a cohort of pregnant women using antihypertensive drugs, we compared exposure to antidepressants versus no exposure and the possible association with birth weight, APGAR scores, NICU admission, and maternal admission to an obstetrical intensive care unit (OHC). It was hypothesized that pregnant women with hypertensive disorders using antidepressants are at greater risk of complications. Methods A retrospective cohort study in a general teaching hospital in Zwolle, in the Middle-Northern part of The Netherlands. Finally, 58 pregnancies in the exposed group and 273 pregnancies in the reference group met all inclusion and exclusion criteria. We compared the neonate’s birthweight between the exposed to antidepressants group and the reference group as the primary outcome. Secondary outcomes were the APGAR score at 1 and 5 min and obstetric high care (OHC) admission of the mother and neonatal intensive care unit (NICU) admission of the child. Results We found no differences in birth weight in neonates of mothers with hypertensive disorders and whether or not to use antidepressants. Besides a possible higher risk of admission to an OHC in women with hypertension-complicated pregnancies using antidepressants, we found no other maternal or neonatal risks in this population. Conclusion We found no additional maternal or neonatal risks of using antidepressants prescribed to women with hypertension disorders during pregnancy.
- 29 January 2024
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 310 (1) , 161-170
Risks associated with antidepressants in patients with hypertension during pregnancy: a retrospective cohort study
Purpose In a cohort of pregnant women using antihypertensive drugs, we compared exposure to antidepressants versus no exposure and the possible association with birth weight, APGAR scores, NICU admission, and maternal admission to an obstetrical intensive care unit (OHC). It was hypothesized that pregnant women with hypertensive disorders using antidepressants are at greater risk of complications. Methods A retrospective cohort study in a general teaching hospital in Zwolle, in the Middle-Northern part of The Netherlands. Finally, 58 pregnancies in the exposed group and 273 pregnancies in the reference group met all inclusion and exclusion criteria. We compared the neonate’s birthweight between the exposed to antidepressants group and the reference group as the primary outcome. Secondary outcomes were the APGAR score at 1 and 5 min and obstetric high care (OHC) admission of the mother and neonatal intensive care unit (NICU) admission of the child. Results We found no differences in birth weight in neonates of mothers with hypertensive disorders and whether or not to use antidepressants. Besides a possible higher risk of admission to an OHC in women with hypertension-complicated pregnancies using antidepressants, we found no other maternal or neonatal risks in this population. Conclusion We found no additional maternal or neonatal risks of using antidepressants prescribed to women with hypertension disorders during pregnancy.
- Open Access
- 15 November 2023
- Published by Springer Nature in Research Square
Risks associated with antidepressants in patients with hypertension during pregnancy: a retrospective cohort study
Objective In a cohort of pregnant women using antihypertensive drugs, we compared exposure to antidepressants versus no exposure and the possible association with birth weight, APGAR scores, NICU admission, and maternal admission to an obstetrical intensive care unit (OHC). It was hypothesized that pregnant women with hypertensive disorders using antidepressants are at greater risk of complications. Setting A retrospective cohort study in a general teaching hospital in Zwolle, in the Middle-Northern part of The Netherlands. Participants We selected 77 pregnancies eligible for the exposed group and 293 eligible for the reference group. Of those, we excluded patients because of twin pregnancy, stillbirth, patients who discontinued antidepressants during pregnancy, and termination of the pregnancy not related to hypertension or mental health problems during pregnancy. Finally, 58 pregnancies in the exposed group and 273 pregnancies in the reference group met all inclusion and exclusion criteria. Outcome We compared the neonate’s birthweight between the exposed to antidepressants group and the reference group as the primary outcome. Secondary outcomes were the APGAR score at 1 and 5 minutes and obstetric high care (OHC) admission of the mother and neonatal intensive care unit (NICU) admission of the child. Results We found no differences in birth weight in neonates of mothers with hypertensive disorders and whether or not to use antidepressants. Besides a possible higher risk of admission to an OHC in women with hypertension-complicated pregnancies using antidepressants, we found no other maternal or neonatal risks in this population. Conclusions We found no additional maternal or neonatal risks of using antidepressants prescribed to women with hypertension disorders during pregnancy.
- 15 November 2023
- Published by Springer Nature in Research Square
Open AccessRisks associated with antidepressants in patients with hypertension during pregnancy: a retrospective cohort study
Objective In a cohort of pregnant women using antihypertensive drugs, we compared exposure to antidepressants versus no exposure and the possible association with birth weight, APGAR scores, NICU admission, and maternal admission to an obstetrical intensive care unit (OHC). It was hypothesized that pregnant women with hypertensive disorders using antidepressants are at greater risk of complications. Setting A retrospective cohort study in a general teaching hospital in Zwolle, in the Middle-Northern part of The Netherlands. Participants We selected 77 pregnancies eligible for the exposed group and 293 eligible for the reference group. Of those, we excluded patients because of twin pregnancy, stillbirth, patients who discontinued antidepressants during pregnancy, and termination of the pregnancy not related to hypertension or mental health problems during pregnancy. Finally, 58 pregnancies in the exposed group and 273 pregnancies in the reference group met all inclusion and exclusion criteria. Outcome We compared the neonate’s birthweight between the exposed to antidepressants group and the reference group as the primary outcome. Secondary outcomes were the APGAR score at 1 and 5 minutes and obstetric high care (OHC) admission of the mother and neonatal intensive care unit (NICU) admission of the child. Results We found no differences in birth weight in neonates of mothers with hypertensive disorders and whether or not to use antidepressants. Besides a possible higher risk of admission to an OHC in women with hypertension-complicated pregnancies using antidepressants, we found no other maternal or neonatal risks in this population. Conclusions We found no additional maternal or neonatal risks of using antidepressants prescribed to women with hypertension disorders during pregnancy.
- Open Access
- 14 June 2023
- Published by Nederlandse Liga tegen Epilepsie in Epilepsie, periodiek voor professionals
- Vol. 22 (2)
Levetiracetam en zwangerschap: relatie tussen concentraties en aanvallen
Optimale behandeling van epilepsie tijdens de zwangerschap is belangrijk voor zowel moeder als kind. De dosering van anti-aanvalsmedicatie moet soms worden aangepast vanwege een snellere eliminatie dan gebruikelijk. In een uitgebreide studie werd de daling van serumconcentraties van levetiracetam en de consequenties hiervan voor de aanvalsfrequentie onderzocht.
- 14 June 2023
- Published by Nederlandse Liga tegen Epilepsie in Epilepsie, periodiek voor professionals
- Vol. 22 (2)
Open AccessLevetiracetam en zwangerschap: relatie tussen concentraties en aanvallen
Optimale behandeling van epilepsie tijdens de zwangerschap is belangrijk voor zowel moeder als kind. De dosering van anti-aanvalsmedicatie moet soms worden aangepast vanwege een snellere eliminatie dan gebruikelijk. In een uitgebreide studie werd de daling van serumconcentraties van levetiracetam en de consequenties hiervan voor de aanvalsfrequentie onderzocht.
- 7 June 2023
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 89 (10) , 3005-3015
Maternal and neonatal outcomes after benzodiazepine and benzodiazepine agonist exposure during pregnancy in women with mental disorders
Aims: To compare the gestational age of neonates in utero exposed to benzodiazepines (BDZs) with nonexposed controls. Secondary objectives were birth weight, presence of congenital malformations, APGAR score and the need for >3 months (prolonged) maternal psychiatric care.Methods: A retrospective cohort study of women and neonates from 2013 to 2021 with univariate and multivariable analysis to study the associations between BDZ exposure and gestational age compared to nonexposed women with mental health problems.Results: We found that BDZ exposure was not associated with a lower gestational age. We found that women in the exposed group had an increased risk of psychiatric care (adjusted odds ratio 2.58 [95% confidence interval 1.71–3.91], P < .001).Conclusion: We found that in utero BDZ exposure was not associated with a significantly lower gestational age of the neonates and was associated with prolonged psychiatric care of their mothers.
- 7 June 2023
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 89 (10) , 3005-3015
Maternal and neonatal outcomes after benzodiazepine and benzodiazepine agonist exposure during pregnancy in women with mental disorders
Aims: To compare the gestational age of neonates in utero exposed to benzodiazepines (BDZs) with nonexposed controls. Secondary objectives were birth weight, presence of congenital malformations, APGAR score and the need for >3 months (prolonged) maternal psychiatric care.Methods: A retrospective cohort study of women and neonates from 2013 to 2021 with univariate and multivariable analysis to study the associations between BDZ exposure and gestational age compared to nonexposed women with mental health problems.Results: We found that BDZ exposure was not associated with a lower gestational age. We found that women in the exposed group had an increased risk of psychiatric care (adjusted odds ratio 2.58 [95% confidence interval 1.71–3.91], P < .001).Conclusion: We found that in utero BDZ exposure was not associated with a significantly lower gestational age of the neonates and was associated with prolonged psychiatric care of their mothers.
- 10 January 2023
- Published by Wolters Kluwer Health in Neurology
- Vol. 100 (2) , E172-E181
Association of Levetiracetam Concentration With Seizure Frequency in Pregnant Women With Epilepsy
Background and Objectives: Pharmacologic treatment of epilepsy in pregnant women is balancing between risks for mother and for fetus. Levetiracetam (LEV) is considered to be safe during pregnancy because of its low teratogenic potential and lack of drug-drug interaction with other anti-seizure medications (ASMs). Recent studies have shown decline of ASM concentrations during pregnancy because of physiologically-based pharmacokinetic changes. In this study, we established this decrease in LEV concentration during pregnancy. Additionally, we aimed at investigating the effect of the low LEV levels during pregnancy and develop a target value for the level during pregnancy. Methods: Pregnant patients using levetiracetam were studied in this retrospective cohort study. Blood samples were monthly collected through venous puncture or the dried blood spot method. ASM serum concentrations were determined at least six months prior to conception and for each month of pregnancy. Seizure frequency and ASM dosages during pregnancy were obtained from patient records. Patients were divided into two groups: a ‘seizure free’ and a ‘non-seizure free’ group which contained pregnancies in which mother had experienced an epileptic seizure more than twelve months and less than twelve months before pregnancy, respectively. Results: We found decreased concentration/dose ratios in 29 pregnancies throughout all months of pregnancy. In the non-seizure free group, it was found that low LEV concentrations were associated with seizure increase frequency (p=0.022). For this group the cut off-value with the highest sum of sensitivity and specificity was 0.466. Discussion: All in all, we recommend therapeutic drug monitoring for all pregnant patients on LEV as the concentrations of LEV significantly decrease throughout most months of pregnancy. However, this decrease in LEV concentration was only significantly correlated with seizure deterioration in patients who had a seizure in the year preceding the pregnancy . Therefore, we suggest more careful monitoring of non-seizure free patients as they are at higher risk for experiencing an increase of seizure frequency. For this group, we advise physicians to keep LEV concentration above 65% of the preconceptional concentration. For seizure free patients we recommend a LEV threshold value of approximately 46% of the preconceptional concentration.
- 10 January 2023
- Published by Wolters Kluwer Health in Neurology
- Vol. 100 (2) , E172-E181
Association of Levetiracetam Concentration With Seizure Frequency in Pregnant Women With Epilepsy
Background and Objectives: Pharmacologic treatment of epilepsy in pregnant women is balancing between risks for mother and for fetus. Levetiracetam (LEV) is considered to be safe during pregnancy because of its low teratogenic potential and lack of drug-drug interaction with other anti-seizure medications (ASMs). Recent studies have shown decline of ASM concentrations during pregnancy because of physiologically-based pharmacokinetic changes. In this study, we established this decrease in LEV concentration during pregnancy. Additionally, we aimed at investigating the effect of the low LEV levels during pregnancy and develop a target value for the level during pregnancy. Methods: Pregnant patients using levetiracetam were studied in this retrospective cohort study. Blood samples were monthly collected through venous puncture or the dried blood spot method. ASM serum concentrations were determined at least six months prior to conception and for each month of pregnancy. Seizure frequency and ASM dosages during pregnancy were obtained from patient records. Patients were divided into two groups: a ‘seizure free’ and a ‘non-seizure free’ group which contained pregnancies in which mother had experienced an epileptic seizure more than twelve months and less than twelve months before pregnancy, respectively. Results: We found decreased concentration/dose ratios in 29 pregnancies throughout all months of pregnancy. In the non-seizure free group, it was found that low LEV concentrations were associated with seizure increase frequency (p=0.022). For this group the cut off-value with the highest sum of sensitivity and specificity was 0.466. Discussion: All in all, we recommend therapeutic drug monitoring for all pregnant patients on LEV as the concentrations of LEV significantly decrease throughout most months of pregnancy. However, this decrease in LEV concentration was only significantly correlated with seizure deterioration in patients who had a seizure in the year preceding the pregnancy . Therefore, we suggest more careful monitoring of non-seizure free patients as they are at higher risk for experiencing an increase of seizure frequency. For this group, we advise physicians to keep LEV concentration above 65% of the preconceptional concentration. For seizure free patients we recommend a LEV threshold value of approximately 46% of the preconceptional concentration.